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Abstract
Objective: Adverse changes in body composition, 
specifically decreased muscle mass (MM) and increased 
fat mass, characterize rheumatoid arthritis (RA). These 
changes, termed rheumatoid cachexia (RC), are important 
contributors to the disability and elevated co-morbidity 
risk of RA. Recently, we observed substantial muscle loss 
(~2kg) in an RA patient following a single intramuscular 
(IM) corticosteroid (CS) injection to treat a disease flare. 
The current study aimed to determine whether this ap-
parent iatrogenic effect of IM CS is typical i.e. does this 
routine, recommended treatment contribute to RC?
Methods: Body composition was assessed by dual-
energy x-ray absorptiometry (DXA) in 8 established RA 
patients who received a 120mg IM methylprednisolone 
injection to treat a disease flare. DXA scans estimated ap-
pendicular lean mass (ALM; a surrogate measure of MM), 
total lean mass (LM), and total and regional adiposity 
at baseline (injection day), and 4-weeks and 6-9 months 
post-injection. Statistical analysis was by 1-way ANOVA’s. 
Copyright: © 2017 Andrew B Lemmey, et al. 
This article is distributed under the terms of the Creative 
Commons Attribution 4. 0 International License 
(http://creativecommons. org/licenses/by/4. 0/), which 
permits unrestricted use, distribution, and reproduction in 
any medium, provided you give appropriate credit to the 
original author(s) and the source. 
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Results: There was significant loss of ALM (-0.93kg, 
P=0.001, 95% CI [-0.49, -1.36]) and a trend towards re-
duced LM (-1.10kg, P=0.165, 95% CI [0.58, -2.79]) at 
4-weeks relative to baseline. At 6-9 months, despite con-
trol of inflammation and disease activity, these losses re-
mained. 
Conclusion: Substantial muscle loss occurred in RA 
patients following IM CS injection to treat a disease flare. 
Thus, this recommended treatment appears to exacer-
bate RC, thereby potentially increasing disability and co-
morbidity risk. If this effect is confirmed by larger studies, 
the role of one-off high-dose CS in the treatment of RA 
should be reviewed. 
Key Messages
•	 Significant loss of muscle mass was observed in 
8 established rheumatoid arthritis (RA) patients 
administered an intramuscular (IM) injection of 
high-dose corticosteroids (CS) to treat a disease 
flare. 
•	 This muscle loss was apparent 4 weeks after injec-
tion and persisted for at least 6-9 months despite 
good control of inflammation and disease activity. 
•	 Given the routine use of this recommended treat-
ment for suppressing high disease activity in RA, 
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IM CS injection is likely to be an important con-
tributor to the muscle loss and, as a consequence, 
the disability that characterise RA. 
•	 These findings raise important concerns about 
the routine use of IM CS injection for RA patients 
with active disease, and justify investigating the 
efficacy of alternative treatments, such as short-
term biologics, for resolving uncontrolled RA. 
Introduction
Patients with rheumatoid arthritis (RA) typically ex-
perience substantial loss of lean mass (LM), primarily 
muscle mass (MM), and increased fat mass (FM), espe-
cially trunk FM, in a process known as ‘rheumatoid ca-
chexia’ (RC) [1]. Thought to be driven by inflammation, 
specifically pro-inflammatory cytokines such as tumour 
necrosis factor (TNF)-α [1], RC is a major contributor to 
the decreased strength and impaired physical function, 
and the exacerbated co-morbidity risk, that characterize 
RA [1-3]. Unfortunately, despite usually achieving good 
control of inflammation and disease activity, current 
treatment of RA does not reverse these adverse changes in 
body composition [3]. 
When RA is ‘active’ (i.e. before starting drug treat-
ment, or during a disease flare in established RA), one-
off high-dose corticosteroids (CS), often administered by 
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intramuscular (IM) injection, is recommended in clini-
cal guidelines [e.g. American College of Rheumatology 
(ACR), 4; European League against Rheumatism (EU-
LAR), 5; British Society for Rheumatology (BSR), 6,7; 
NICE Clinical Guidelines 79, 2009, 8]. This treatment has 
been shown to rapidly reduce inflammation and pain in 
RA [e.g., 6,7]. While long term high-dose CS treatment is 
known to have detrimental effects on body composition 
including loss of lean mass (LM) and an increase in FM 
[e.g., 9], the effects on body composition of single high-
dose CS treatment, including IM CS injection, are unclear. 
Our interest in the body composition effects of acute 
CS treatment was stimulated by the observation of a sub-
stantial loss of dual-energy x-ray absorptiometry (DXA)-
assessed muscle mass (-2.0 kg in appendicular LM, ALM; 
i.e. ~7% of total ALM) in an RA patient following a single 
CS injection given to treat a disease flare [10]. A search 
of the literature revealed only one other case report of lo-
cal muscle loss following CS injection [11]. However, in 
this report assessment of muscle loss was only made by 
visual observation. Nonetheless, these two reported cases 
raise concerns that high-dose CS injection treatment may 
be contributing to the reduced MM which we recently 
reported persists even in aggressively, and successfully, 
pharmacologically-treated contemporary RA patients [3]. 
To our knowledge, this pilot study is the first to in-
vestigate the effects on body composition of a single high-
dose IM CS injection. We hypothesized that this routine, 
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recommended treatment for high RA disease activity ex-
acerbates muscle loss, and thus could contribute to the 
impaired physical function seen in patients with RA. 
Subjects and Methods
This pragmatic, uncontrolled, pre-post intervention-
pilot study was approved by the North Wales Research 
Ethics Committee – West (15/WA/0013). 
Established RA patients presenting with a disease 
flare and treated with an IM injection of CS were recruited 
from rheumatology outpatient clinics of the Peter Mad-
dison Rheumatology Centre, Llandudno Hospital. For 
inclusion, participants had to: (a) fulfil the American Col-
lege of Rheumatology/EULAR 2010 revised classification 
criteria for the diagnosis of RA; (b) have uncontrolled RA 
disease activity for which IM CS injection was deemed 
appropriate treatment; (c) be aged ≥18 years; (d) not be 
cognitively impaired; (e) be free of other cachectic dis-
eases or conditions; (f) not be pregnant; and (g) not have 
any contraindication to high-dose IM CS injection (e.g. , 
uncontrolled diabetes mellitus, active infection, previous 
hypersensitivity to CS injections). 
Active disease (i.e. flare) was determined by the at-
tending consultant rheumatologist following clinical as-
sessment. If considered appropriate by the same rheuma-
tologist, and patient consent was obtained, a standard CS 
injection, 120 mg of depomedrone (methylprednisolone 
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acetate aqueous solution), was administeredinto the glu-
teal muscle. 
DXA-scans were performed within one hour of the 
patient receiving the injection, and repeated following 
routine rheumatology follow-up clinics at approximately 
four weeks (27-32 days) and 6-9 months post-injection. 
Patient’s disease activity (Disease Activity Score in 28 
joints, DAS28-CRP) and systemic inflammation (C-re-
active protein, CRP) were also determined at baseline, 
4-weeks and 6-9 months. 
Body Composition Measures 
Total and regional lean and fat masses, along with 
bone mineral content (BMC) and density (BMD), were 
estimated using a whole body fan-beam DXA scanner 
(Hologic, QDR Discovery 45615, software V12.4). ALM 
(the summed LM of the arms and legs) served as a sur-
rogate measure of total body MM [3]. The in-house coef-
ficient of variation of 1.4% of our scanner complies with 
manufacturer’s guidelines [3]. 
Statistical Analysis 
The primary outcome measure was DXA-assessed 
ALM, with secondary outcome measures of: disease activ-
ity (DAS28-CRP) and systemic inflammation (CRP), and 
other body composition variables: total LM, % ALM rela-
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tive to body mass (BM)(ALM/BM%), total FM, trunk FM, 
% FM relative to BM (% body fat),% trunk FM relative to 
total FM (trunk FM%), BMC and BMD. 
Data analyses was by 1-way ANOVAs (3 time-points), 
with effect size (small = 0.20-0.49; medium = 0.50-0.79; 
large ≥ 0.80) calculated for each variable. Data analyses 
was performed using the Statistical Package for the Social 
Sciences 22 (SPSS) (Chicago, USA). Data is presented as 
mean (±SD), with between-time differences presented as 
mean (±95% confidence intervals; 95% CI), and, where 
appropriate, range is also given. Significance was set at P 
<0.05. 
Results
Nine RA patients who received an IM CS injection to 
treat a flare of disease were deemed eligible for the study, 
and consented to participate. Assessments at baseline, 
4-weeks and 6-9 months post-injection were performed 
on 8 patients, as 1 participant withdrew from the study 
after baseline measurements due to suspected meningi-
tis. The mean interval between CS injection and baseline 
DXA-scan was 0.7 hours (~42 minutes; range: 18-60 min-
utes). 
Table 1 shows the baseline demographic data for 
the eight patients who completed the study. All patients 
had established disease (mean duration ~11 years, range: 
10 www.avidscience.com
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2.0-46.8 years), and were on standard disease-modifying 
anti-rheumatic drug (DMARD) therapy. None of these 
patients, either at the time of the CS injection or over the 
ensuing 6-9 months, were treated with biologics or oral 
steroids. Patients reported no substantial changes to life-
style (e.g., diet or exercise), or adverse health events, over 
the trial period. 
Table 1: Baseline demographics of rheumatoid arthritis patients re-
ceiving intra-muscular corticosteroid injection to treat a disease flare 
(n=8). 
Data presented as mean (±SD). DAS28 = Disease Activity Score in 28 
joints; CRP = C-reactive protein. 
Significant reductionsin DAS28-CRP (P=0.049, 95% 
CI [-0.82, -2.30]) and CRP (P=0. 023, 95% CI [-0. 78, -28. 
95]) from baseline to 4-weeks indicated that the patients 
were responsive to the anti-inflammatory effects of IM CS 
(Table 2). This response is also reflected in 5/8 patients ex-
periencing clinically meaningful improvements in DAS28 
(reduction >1.2) and CRP (reduction >10mg/L) in the 4 
weeks following CS injection (Table 2). 
Age (years) 61. 4 (±7. 2)
Sex (n female) (%) 6 (75)
Disease duration (months) 130. 5 (±158. 8)
DAS28-CRP 4. 51 (±0. 97)
CRP (mg/L) 23. 4 (±20. 9)
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Table 2: Individual changes in DAS28-CRP score, component DAS28-
CRP scores, and ALM over 4 weeks following a single, high-dose in-
tramuscular corticosteroid injection to treat a rheumatoid arthritis 
disease flare. 
DAS28 = Disease Activity Score in 28 joints; CRP = C-reactive pro-
tein; VAS = visual analogue scale; ALM = appendicular lean mass; SD 
= standard deviation. 
Mean body composition changes are shown in Table 
3. Four weeks following IM CS injection, an average of 0. 
93 kg ALM (i.e. muscle mass) was lost, whilst mean total 
LM was reduced by 1.10 kg. All 8 patients lost ALM fol-
lowing IM CS injection, with 7 losing >0.50 kg (Table 2). 
Mean proportional ALM (ALM/BM%, i.e. relative MM) 
was significantly reduced at 4-weeks post injection. Al-
though all mean measures of adiposity increased over 
this period, i.e. total FM (+0.70 kg), trunk FM (+0.53 kg), 
% body fat (+0.89%) and trunk FM % (+1.01%), none of 
these changes were statistically significant. No changes in 
bone mineral density or bone mineral content were de-
tected at 4-weeks (data not shown; P’s=0.620, 0.664, re-
spectively). 





Baseline 4-weeks Baseline 4-weeks Baseline 4-weeks Baseline 4-weeks Baseline 4-weeks
1 4.42 1.66 17 5 4 0 8 0 20 4 1.02
2 3.42 1.54 4 4 0 0 4 0 54 0 0.56
3 4.93 2.90 67 15 1 0 4 1 75 27 1.92
4 5.20 4.42 5 5 11 3 6 8 75 53 0.86
5 3.69 2.28 20 5 7 2 0 0 64 20 1.42
6 3.28 2.86 40 19 4 1 0 0 30 39 0.62
7 5.96 3.40 20 5 3 4 15 3 89 19 0.31







8.5 (5.7) 4.8    
(3.8)
2.6   
(3.7)
6.0   
(5.2)










Table 3: Body composition changes over 4 weeks following a single, 
high-dose intramuscular corticosteroid injection to treat a rheuma-
toid arthritis disease flare. 
Data presented as mean (±SD), unless stated otherwise. DXA = dual 
x-ray absorptiometry; CS = corticosteroid; CI = confidence interval; 
ALM = appendicular lean mass; BM = body mass; LM = lean mass; 
FM = fat mass; * P <.05; Effect size: small = 0.20-0.49; medium = 0.50-
0.79; large ≥ 0.80. 
There was no significant change, or trend toward 
change, in any of the body composition measures be-
tween the follow-up assessments at 4-weeks and 6-9 
months (P’s=0.32-0.54), during which time control of 
inflammation and disease activity was maintained. Thus, 
6-9 months after IM CS injection, the depletion in ALM 
observed at 4-weeks had not spontaneously reversed and 
patients remained significantly muscle reduced relative to 
their baseline levels. 




% difference P Effect 
size
ALM (kg) 19.86 (±1.71) 18.93 (±1.57) -0.93 
[-0.49, -1.36]
-4.7 0.001* 0.54
ALM/BM % 25.7 (±2.6) 24.8 (±3.0) -0.91 
[-0.42, -1.40]
-3.1 0.003* 0.33
Total LM (kg) 48.02 (±5.32) 46.91 (±5.10) -1.11 
[-0.58, -2.79]
-2.3 0.165 0.21
Total FM (kg) 31.81 (±6.27) 32.51 (±6.29) 0.70 
[-0.99, 2.39]
2.2 0.362 0.11
Body fat %      
(total FM/BM %)
35.1 (±9.9) 36.0 (±11.0) 0.89 
[-0.66, 2.43]
2.5 0.216 0.09
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Discussion
To our knowledge, this study is the first to objec-
tively investigate the consequences of a single, high-dose 
administration of corticosteroids on body composition. 
Although only preliminary, results from eight patients, 
taken with a similar observation from our case study [10], 
suggest that a single, high-dose IM CS injection used to 
treat active RA disease results in significant loss of ALM - 
a surrogate measure of skeletal MM. As this reduction in 
MM is likely to have adverse effects on physical function, 
these findings raise important concerns about the routine 
use of thistreatment for RA patients with active disease. 
Patients presenting with uncontrolled RA are often 
treated by IM CS injection. Indeed, such injections are 
recommended by national guidelines for the management 
of active RA [e.g. ACR, 4; EULAR, 5; BSR, 6,7; NICE, 8] 
because of their efficacy in rapidly attenuating inflamma-
tion and pain. Consistent with these recommendations 
and its regularly observed clinical benefit, the CS injec-
tions administered in this study ameliorated disease ac-
tivity and inflammation, with mean DAS28 and CRP at 
4 weeks being reduced, relative to baseline, by 35% and 
64%, respectively. 
However, despite rapidly restoring control of inflam-
mation and disease activity, there was a mean loss of 0.93 
kg ALM (i.e. skeletal muscle) in the 4 weeks following IM 
CS injection. This apparent iatrogenic loss of ALM ac-
counts for approximately 37% of the discrepancy in pro-
14 www.avidscience.com
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portional MM (i.e. ALM/BM %) between RA patients and 
healthy age- and sex-matched individuals we have previ-
ously reported [3]. Additionally, reduced MM, including 
the magnitude of MM loss observed in this study (~5% 
of total MM), is acknowledged as a major contributor 
to the decreased strength and impaired physical func-
tion characteristic of RA [e.g., 1-3]. Further, loss of MM 
(and therefore loss of ‘expendable’ protein) impairs the 
immune system’s ability to adequately respond to infec-
tion and trauma [2]. It is important to note that despite 
sustained low disease activity, the muscle lost at 4-weeks 
was not spontaneously restored by the 6-9 month post-
injection follow-up assessment. This finding is not unex-
pected, as without some form of anabolic stimuli the body 
does not spontaneously recover lost MM; and in specific 
regard to RA patients, this remains the case even when 
disease remission is achieved [3]. This further emphasises 
the importance for adjunct interventions designed to in-
crease MM in RA. Of the potential anabolic interventions 
trialled, progressive resistance training [e.g., 12] is clearly 
the most beneficial intervention for improving both MM 
and physical functioning in RA patients. 
With regard to the muscle loss we observed, an obvi-
ous question is whether this was a consequence of the in-
flammation associated with the disease flare. In response 
to this, we consider that systemic inflammation was un-
likely to be a major contributor to the ALM loss seen in 
this study because of i) the rapidity of the anti-inflamma-
15
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tory effects of high-dose CS, ii) the meaningful muscle loss 
(> 0.5kg ALM) following IM CS injection experienced by 
subjects (#2,4; Table 2) who did not have systemic inflam-
mation according to blood CRP level at baseline, and iii) 
the lack of association (determined by linear regression) 
between ALM loss and either DAS28 or CRP at baseline 
(R2=0.009, P=0.822; R2=0.063, P=0.549, respectively). 
Additionally, our findings of reduced MM following IM 
CS injection are consistent with the established effect on 
skeletal muscle of chronic high dose CS treatment. While 
the exact mechanism underlying glucocorticoid-induced 
reduction in MM is unclear, augmented muscle protein 
breakdown via stimulation of the catabolic ubiquitin-pro-
teasome system bought about by increased expression of 
atrogenes (genes, such as FOXO, Atrogin-1 and MuRF-1, 
involved in muscle atrophy), and attenuated muscle pro-
tein synthesis via inhibitionof anabolic pathways (e.g. , 
mTOR/S6 kinase 1, PI3K/Akt and insulin-like growth fac-
tor (IGF)-I), have been observed [for a review see 13]. 
Given that IM CS injection is often administered to 
patients following diagnosis of RA, and again when pa-
tients with established RA experience disease flares, it is 
not unusual for RA patients to receive this form of treat-
ment several times during the course of their disease (3 
occasions (range: 2-4) on average for the patients in the 
current study). Thus, this recommended treatment could 
be a significant contributor to rheumatoid cachexia, and 




Chronic CS use has also been implicated in the re-
distribution of fat to the truncal area [14]. Although we 
saw no mean change in patients’ total FM, we did observe 
a non-significant 3.5% increase in trunk FM% following 
acute administration of high-dose CS. As such, this is an-
other aspect of body composition that warrants attention 
in a future large study evaluating the effects of one-off 
high-dose CS treatment. A shift in adiposity, if confirmed, 
would be worrying as trunk obesity, a feature of RA body 
composition [2, 3], exacerbates CVD risk [15]. Although 
chronic [e.g., 14] and acute IM CS [16] use is known to in-
creaseosteoporosis risk, we saw no changes in bone meas-
ures (BMD or BMC). 
We acknowledge several limitations of our pilot study. 
First, the low n of our sample, and the inclusion of only 
patients with established RA who were experiencing a dis-
ease flare. These make it difficult to generalise the effect of 
IM CS injection we observed toall RA patients, notably 
recently-diagnosed RA patients. Accordingly, to confirm 
the generality of these body composition effects of IM CS 
treatment for active RA, we have recently commenced a 
large, clinic-based study (n~100) which will mostly in-
clude treatment-naïve recently-diagnosed RA patients. 
However, in defence of the results from our pilot study, we 
feel that the very consistent pattern of muscle loss (Table 2, 
plus our case study [10]) justifies concerns that IM CS in-
jection may cause clinically meaningful muscle loss in RA 
patients. The lack of random and controlled treatment as-
signment may also be considered a weakness of our study 
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design. However, this was unavoidable in a pragmatic, 
observational study of routine clinical practice. Addition-
ally, denying treatment to patients with highly-active RA 
would be unethical. 
In summary, the results from this pilot study indicate 
that a single IM injection of high-dose CS, a recommend-
ed and standard treatment for uncontrolled disease activ-
ity in RA, causes substantial and clinically relevant loss 
of MM. Since short-term, high-dose treatment with CS, 
including administration by IM injection, is undoubtedly 
the most cost-effective treatment currently available to 
combat high levels of inflammation in RA, we are not sug-
gesting that this treatment is discontinued, as unresolved 
inflammation will also result in muscle loss [1]. However, 
we are advocating that ways of attenuating this apparent 
iatrogenic effect of IM CS injection should be investigat-
ed, as should potential alternative treatments for rapidly 
resolving the inflammation and pain of uncontrolled RA. 
In regard to alternative treatments, the efficacy of short-
term biologic warrants trialling, with the anti-IL-6 recep-
tor blocker, tocilizumab, and the interleukin-1 receptor 
antagonist, anakinra, appearing the most likely candidates 
due to their more rapid treatment response. 
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